Immunex Corp. (NASDAQ:IMNX) announced that the Securitiesand Exchange Commission has declared effective the jointproxy and registration statement concerning its proposedmerger with the Lederle Oncology Corp. subsidiary of AmericanCyanamid Co. (NYSE:ACY). Immunex shareholders must stillvote their approval before the merger, first announced inDecember 1992, is completed. Shareholders of record in theSeattle company as of April 2 will get to cast their votes at aspecial meeting, scheduled for June 1.
(c) 1997 American Health Consultants. All rights reserved.